Figure 2
Disease-free survival (A) and overall survival (B) treated with or without EGFR TKIs after complete resection in the propensity-matched cohort of EGFR-mutant NSCLC patients.
Figure 2 | Scientific Reports
Disease-free survival (A) and overall survival (B) treated with or without EGFR TKIs after complete resection in the propensity-matched cohort of EGFR-mutant NSCLC patients.
